Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

NCT02669914 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT02669914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02669914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Terminated
Start date
September 12, 2016
Completion date
January 11, 2018
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cancer of breast, cancer of kidney, cancer of ovary, cancer of the breast, cancer of the kidney, cancer of the ovary, cancer of the pancreas, colorectal cancer, colorectal carcinoma, gastroesophageal cancer, kidney cancer, non-small cell lung cancer, nonsmall cell lung cancer, ovarian cancer, ovary cancer, pancreatic cancer, renal cancer